Paper
Postmarketing Surveillance Study of OxyContin® Tablets for Relieving Moderate to Severe Cancer Pain
Published Aug 1, 2008 · Shi-ying Yu
Oncology
10
Citations
0
Influential Citations
Abstract
Objective: To evaluatethe efficacy and safety of OxyContin® tablets (controlled-release oxycodone hydrochloride: 5, 10, 20, and 40 mg) in relieving moderate to severe cancer pain. Method: A multicenter, open-label, prospective, self-controlled clinical trial was used. Results: Pain was relieved in 89.1% of patients within 1 h after drug administration. OxyContin® tablets showed good clinical efficacy in relieving both moderate and severe cancer pain. Compared with baseline average pain scores of 6.9 ± 1.4, subjects had lower average pain scores after administration of OxyContin® tablets: 2.7 ± 1.8 after 1 week and 2.1 ± 1.5 after 2 weeks. Response rate reached 75.0% at the end of the 1st week and was maintained at approximately 90% from the 3rd to the 8th week. The most common adverse drug reactions (ADRs) caused by OxyContin®tablets were, in descending order of incidence rate: constipation (25.5%), nausea (13.3%), vomiting (6.2%), lethargy (3.7%), and dysuria (2.1%). All these ADRs could be decreased by preventive medications. Conclusion: OxyContin® tablets demonstrated fast onset of cancer pain control, superior efficacy in relieving both moderate and severe cancer pain and a good safety profile.
Non-RCTOxyContin® tablets provide fast onset of cancer pain relief, superior efficacy in relieving moderate to severe cancer pain, and a good safety profile.
Full text analysis coming soon...